Question

Develop Novel Antibodies against COVID-19 Disease Think about a new treatment to target the pandemic new coronavirus using monoclonal antibodies or/& polyclonal antibodies. a. Describe how you will practically produce it in the lab. b. List the major challenges Maximum 1000 words. Minimum 370 words

pay attention to the points that required it needs to include monoclonal ab or/and polyclonal ab

Answer 1

Enetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.

a) Programs can start at cell line development or we can transfer in existing cell lines or processes.

Flexible solutions across multiple sites.

Extensive experience at all clinical phases (from pre-clinical development to late phase to commercial production).

Common platforms e.g. GE 500L & 2000L SUBs.

Monoclonal antibody dedicated facilities.

Option to align existing processes with common Fujifilm Diosynth Biotechnologies monoclonal antibody processes to maximize operational efficiency.

b)

The Guardian reported that Maryland (USA)-based Novavax is trying to construct a "recombinant" vaccine.

This involves extracting the genetic code for the protein spike on the surface of Sars-CoV-2, which is the part of the virus most likely to induce an immune response in humans, and pasting it into the genome of a bacterium or yeast – forcing these microorganisms to churn out large quantities of the protein.

Other approaches, even newer, bypass the protein and build vaccines from the genetic instruction itself. This is the case for Moderna and another Boston company, CureVac, both of which are building Covid-19 vaccines out of messenger RNA.

The main concern in this regard is making sure the vaccine gets to all those who need it.

While this is a challenge even within countries, during a pandemic situation, countries also have to compete with each other for medicines.

Pandemics affect those countries that have the most fragile and underfunded healthcare systems, the most.

It should be noted that there is an inherent imbalance between need and purchasing power when it comes to vaccines.